Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
P/B ratio for Medpace Holdings, Inc. (MEDP)
P/B ratio as of 2023: 16.85
According to Medpace Holdings, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 16.85. At the end of 2022 the company had a P/B ratio of 17.80.
P/B ratio history for Medpace Holdings, Inc. from 2013 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 16.85 |
| 2022 | 17.80 |
| 2021 | 8.19 |
| 2020 | 6.16 |
| 2019 | 4.15 |
| 2018 | 3.19 |
| 2017 | 2.81 |
| 2016 | 2.11 |
| 2015 | 2.66 |
| 2014 | 2.03 |
| 2013 | 0.00 |